0000012208false00000122082023-04-252023-04-250000012208us-gaap:CommonClassAMember2023-04-252023-04-250000012208us-gaap:CommonClassBMember2023-04-252023-04-25


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report:   April 25, 2023
(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928
 
Delaware 94-1381833
(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)
 
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
 
(510)724-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   





ITEM 5.07. Submission of Matters to a Vote of Security Holders.

Bio-Rad Laboratories, Inc. (the “Company”) held its Annual Meeting of Stockholders on April 25, 2023. The matters voted upon at the meeting and the results of those votes are set forth below.

1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:
Class of
Common Stock

Votes

Votes

Votes

Broker
to ElectForAgainstAbstainingNon-Votes

Melinda LitherlandClass A
14,950,990
5,818,104
4,785
1,695,304
Arnold A. PinkstonClass A
15,729,846
5,037,217
6,816
1,695,304
Jeffrey L. EdwardsClass B
4,974,972
275
90
56,255
Gregory K. HinckleyClass B
4,974,972
275
90
56,255
Allison SchwartzClass B
4,972,669
2,578
90
56,255
Norman SchwartzClass B
4,972,669
2,578
90
56,255
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
VotesVotesVotesBroker
ForAgainstAbstainingNon-Votes
7,258,29819,666547
-
3. The non-binding advisory vote to approve executive compensation was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
VotesVotesVotesBroker
ForAgainstAbstainingNon-Votes
6,772,070277,4973,158225,785

4With respect to the non-binding advisory vote on the frequency of future advisory votes to approve executive compensation, Three Years received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
VotesVotesVotesVotesBroker
1 Year2 Years3 YearsAbstainingNon-Votes
1,575,55014,4325,461,754989225,785

Consistent with the preferred frequency expressed by the Company's stockholders and the determination of the Company’s Board of Directors, the Company has determined that it will hold a non-binding advisory vote to approve executive compensation every Three Years, until the next required non-binding advisory vote on the frequency of future non-binding advisory votes to approve executive compensation.

5. The stockholder proposal regarding political disclosure was not approved since the proposal did not receive the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
VotesVotesVotesBroker
ForAgainstAbstainingNon-Votes
1,100,1545,935,08117,489225,785



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  
  BIO-RAD LABORATORIES, INC.
   
Date:May 1, 2023By:/s/ Timothy S. Ernst
   Timothy S. Ernst
   Executive Vice President, General Counsel and Secretary


Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Bio Rad Laboratories Charts.
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Bio Rad Laboratories Charts.